Alector, Inc. - Common Stock (NQ:ALEC)

1.870 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Alector, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

February 27, 2024

From Alector, Inc.

Via GlobeNewswire

Earnings Scheduled For February 27, 2024 ↗

February 27, 2024

Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million.

Via Benzinga

Earnings Outlook For Alector ↗

February 26, 2024

Via Benzinga

Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call

February 20, 2024

Call Scheduled for Tuesday, February 27, 2024, at 4:30 p.m. ET/1:30 p.m. PT

From Alector, Inc.

Via GlobeNewswire

Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’s Disease

February 08, 2024

The trial, being conducted in partnership with GSK, is expected to enroll approximately 282 patients globally

From Alector, Inc.

Via GlobeNewswire

Why Alector (ALEC) Stock Is Diving Today ↗

January 17, 2024

Alector shares are trading lower by 14.9% during Wednesday's session. The company announced the pricing of a $75 million public offering.

Via Benzinga

FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)

February 07, 2024

From Alector, Inc.

Via GlobeNewswire

Brain Disease Cures: 3 Neuroscience Stocks Targeting Revolutionary Breakthroughs ↗

January 23, 2024

These three companies are developing treatments for brain diseases that have a great deal of potential, making them top neuroscience stocks.

Via InvestorPlace

Alector Announces Closing of Public Offering

January 19, 2024

From Alector, Inc.

Via GlobeNewswire

SolarEdge Technologies, Calavo Growers, Fisker And Other Big Stocks Moving Lower On Wednesday ↗

January 17, 2024

U.S. stocks traded lower, with the Nasdaq Composite falling more than 150 points on Wednesday.

Via Benzinga

Topics Stocks

Expert Ratings for Alector ↗

December 12, 2023

Via Benzinga

Why Airspan Networks Shares Are Trading Higher By Over 380%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

January 17, 2024

Shares of Airspan Networks Holdings Inc. (NASDAQ: MIMO) shares rose sharply during Wednesday’s session after the company announced a partnership with GCT Semiconductor to develop an RF module. Airspan...

Via Benzinga

Alector Announces Pricing of Public Offering of Common Stock

January 17, 2024

From Alector, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

January 16, 2024

Via Benzinga

Alector Announces Proposed Public Offering of Common Stock

January 16, 2024

From Alector, Inc.

Via GlobeNewswire

Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024 ↗

January 05, 2024

Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.

Via Investor's Business Daily

Constellation Energy, Battalion Oil And Other Big Stocks Moving Higher On Friday ↗

December 15, 2023

U.S. stocks traded mixed, with the Nasdaq Composite gaining around 60 points on Friday. Here are some other big stocks recording gains in today’s session.

Via Benzinga

Topics Stocks

Alector Upgraded, Analyst Sees High Reward Potential Ahead of Alzheimer's Disease Candidate's Phase 2 Results ↗

December 14, 2023

Stifel has upgraded Alector Inc (NASDAQ: ALEC), noting that while Alzheimer's is a very high risk, the probability of success for AL002 (TREM2 agonist) is above average, and the stock risk/reward is...

Via Benzinga

Jabil Posts Upbeat Earnings, Joins Moderna, Rivian Automotive And Other Big Stocks Moving Higher On Thursday ↗

December 14, 2023

U.S. stocks traded higher, with the Nasdaq Composite gaining around 75 points on Thursday.

Via Benzinga

Topics Stocks

Harmonic To Rally Over 80%? Here Are 10 Top Analyst Forecasts For Thursday ↗

December 14, 2023

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Why Amtech Systems Shares Are Trading Higher By Over 30%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

December 14, 2023

Shares of Amtech Systems, Inc. (NASDAQ: ASYS) shares fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter sales results and issued first-quarter sales...

Via Benzinga

These biotechs targeting multiple neurodegenerative diseases

December 01, 2023

A growing number of up-and-coming biotech firms are demonstrating the value of expanding a drug's total addressable market.

Via MarketBeat

Alector to Host Two Virtual Research and Development Events Highlighting TREM2 and Progranulin Programs

November 28, 2023

Leading scientific and clinical experts to provide perspectives and rationale for TREM2 and progranulin targets on December 7 and December 13, respectively

From Alector, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

November 14, 2023

Via Benzinga

Why Edible Garden Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

November 13, 2023

Edible Garden AG Incorporated (NASDAQ: EDBL) shares fell on Monday following third-quarter results.

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

November 13, 2023

Via Benzinga

Alector to Participate in the Stifel Healthcare Conference

November 08, 2023

From Alector, Inc.

Via GlobeNewswire

Alector Reports Third Quarter 2023 Financial Results and Provides Business Update

November 07, 2023

From Alector, Inc.

Via GlobeNewswire

Alector Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)

October 27, 2023

From Alector, Inc.

Via GlobeNewswire

Why Brainstorm Cell Therapeutics Shares Are Trading Lower By 33%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

September 25, 2023

Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares jumped 308% to $2.71 after the company announced pre-clinical gliblastoma results with its lead candidate, TTX-MC138.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.